PepGen - Public Comps and Valuation Multiples

PepGen Overview

About PepGen

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Founded

2018

HQ

Employees

Website

pepgen.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$65.6M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

PepGen Financials

PepGen has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, PepGen achieved revenue of n/a and an EBITDA of -$92.5M.

PepGen expects next 12-month revenue of XXX and NTM EBITDA of XXX

See PepGen valuation multiples based on analyst estimates

PepGen P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$83.9M	-$92.5M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	-$69.1M	-$78.6M	XXX	XXX	XXX
Net Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

PepGen Stock Performance

As of April 15, 2025, PepGen's stock price is $1.

PepGen has current market cap of $36.0M, and EV of -$65.6M.

See PepGen trading valuation data

PepGen Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
-$65.6M	$36.0M	XXX	XXX	XXX	XXX	$-2.80

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

PepGen Valuation Multiples

As of April 15, 2025, PepGen has market cap of $36.0M and EV of -$65.6M.

PepGen's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate PepGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for PepGen and 10K+ public comps

PepGen Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	-$65.6M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	0.7x	XXX	XXX	XXX
P/E	-0.4x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	0.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PepGen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

PepGen Valuation Multiples

PepGen's NTM/LTM revenue growth is n/a

PepGen's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.

Over next 12 months, PepGen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate PepGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for PepGen and other 10K+ public comps

PepGen Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	10%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$1.2M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry